Naproxen

Generic Name: Naproxen

Brand Names: Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₄O_₃

CAS Number: 22204-53-1

Unique Ingredient Identifier: 57Y76R9ATQ

Background: Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, nap...

Indication: Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskelet...

Associated Conditions: Acute Gouty Arthritis, Acute Migraine, Ankylosing Spondylitis (AS), Back pain, Bursitis, Extra-Articular Rheumatism, Fever, Flu caused by Influenza, Headache, Juvenile Idiopathic Arthritis (JIA), Menstrual Distress (Dysmenorrhea), Migraine, Muscle Spasms, Nasal Congestion, Osteoarthritis (OA), Pain, Post Traumatic Pain, Postoperative pain, Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Seasonal Allergic Rhinitis, Sinusitis, Tendinitis, Toothache, Articular inflammation

Associated Therapies: -

Clinical Trials

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: ADL5859
Drug: Naproxen

First Posted Date: 2008-02-29

Last Posted Date: 2015-07-01

Lead Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Target Recruit Count: 46

Registration Number: NCT00626275

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Daytona Beach, Florida, United States
🇺🇸
New England Research Associates, Trumbull, Connecticut, United States
🇺🇸
The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States

and more 5 locations

Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial

Phase 4

Conditions: Pain, Postoperative

Interventions: Drug: naproxen
Drug: placebo

First Posted Date: 2008-02-14

Last Posted Date: 2008-02-14

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 24

Registration Number: NCT00615875

Locations: 🇨🇦
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)

Phase 3

Completed

Conditions: Musculoskeletal Complications
Pain
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: naproxen
Other: placebo

First Posted Date: 2008-01-28

Last Posted Date: 2015-11-09

Lead Sponsor: Gary Morrow

Target Recruit Count: 510

Registration Number: NCT00602420

Locations: 🇺🇸
CCOP - Virginia Mason Research Center, Seattle, Washington, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
CCOP - Evanston, Evanston, Illinois, United States

and more 13 locations

Bunionectomy Study (0000-063)

Phase 1

Completed

Conditions: Acute Pain

Interventions: Drug: pregabalin
Drug: naproxen sodium

First Posted Date: 2008-01-28

Last Posted Date: 2015-04-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 100

Registration Number: NCT00601458

Naproxen for the Prevention of HO After Complex Elbow Trauma

Phase 4

Withdrawn

Conditions: Heterotopic Ossification

Interventions: Drug: Naproxen

First Posted Date: 2008-01-04

Last Posted Date: 2012-03-21

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00586365

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

RN624 In Adult Patients With Chronic Low Back Pain

Phase 2

Completed

Conditions: Low Back Pain

Interventions: Drug: Placebo
Drug: PF-04383119 (RN624)
Drug: Naproxen

First Posted Date: 2008-01-02

Last Posted Date: 2021-07-12

Lead Sponsor: Pfizer

Target Recruit Count: 220

Registration Number: NCT00584870

Locations: 🇺🇸
Wake Internal Medicine Consultants, Inc., Raleigh, North Carolina, United States
🇺🇸
Pinnacle Research Group LLC, Anniston, Alabama, United States
🇺🇸
Radiant Research - Phoenix Southeast, Chandler, Arizona, United States

and more 33 locations